These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

647 related articles for article (PubMed ID: 23780461)

  • 1. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke.
    Saver JL; Fonarow GC; Smith EE; Reeves MJ; Grau-Sepulveda MV; Pan W; Olson DM; Hernandez AF; Peterson ED; Schwamm LH
    JAMA; 2013 Jun; 309(23):2480-8. PubMed ID: 23780461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.
    Fonarow GC; Zhao X; Smith EE; Saver JL; Reeves MJ; Bhatt DL; Xian Y; Hernandez AF; Peterson ED; Schwamm LH
    JAMA; 2014 Apr 23-30; 311(16):1632-40. PubMed ID: 24756513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Thrombolytic Door-to-Needle Time and 1-Year Mortality and Readmission in Patients With Acute Ischemic Stroke.
    Man S; Xian Y; Holmes DN; Matsouaka RA; Saver JL; Smith EE; Bhatt DL; Schwamm LH; Fonarow GC
    JAMA; 2020 Jun; 323(21):2170-2184. PubMed ID: 32484532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Outcomes of Intravenous tPA in Acute Ischemic Stroke Patients With Prior Stroke Within 3 Months: Findings From Get With The Guidelines-Stroke.
    Shah S; Liang L; Kosinski A; Hernandez AF; Schwamm LH; Smith EE; Fonarow GC; Bhatt DL; Feng W; Peterson ED; Xian Y
    Circ Cardiovasc Qual Outcomes; 2020 Jan; 13(1):e006031. PubMed ID: 31903770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous Tissue Plasminogen Activator in Stroke Mimics.
    Ali-Ahmed F; Federspiel JJ; Liang L; Xu H; Sevilis T; Hernandez AF; Kosinski AS; Prvu Bettger J; Smith EE; Bhatt DL; Schwamm LH; Fonarow GC; Peterson ED; Xian Y
    Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005609. PubMed ID: 31412730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis: a retrospective analysis of the Get With the Guidelines-Stroke registry.
    Romano JG; Smith EE; Liang L; Gardener H; Camp S; Shuey L; Cook A; Campo-Bustillo I; Khatri P; Bhatt DL; Fonarow GC; Sacco RL; Schwamm LH
    JAMA Neurol; 2015 Apr; 72(4):423-31. PubMed ID: 25642650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator.
    Xian Y; Liang L; Smith EE; Schwamm LH; Reeves MJ; Olson DM; Hernandez AF; Fonarow GC; Peterson ED
    JAMA; 2012 Jun; 307(24):2600-8. PubMed ID: 22735429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment With Tissue Plasminogen Activator in the Golden Hour and the Shape of the 4.5-Hour Time-Benefit Curve in the National United States Get With The Guidelines-Stroke Population.
    Kim JT; Fonarow GC; Smith EE; Reeves MJ; Navalkele DD; Grotta JC; Grau-Sepulveda MV; Hernandez AF; Peterson ED; Schwamm LH; Saver JL
    Circulation; 2017 Jan; 135(2):128-139. PubMed ID: 27815374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of in-hospital death and symptomatic intracranial hemorrhage in patients with acute ischemic stroke treated with thrombolytic therapy: Paul Coverdell Acute Stroke Registry 2008-2012.
    Tong X; George MG; Yang Q; Gillespie C
    Int J Stroke; 2014 Aug; 9(6):728-34. PubMed ID: 24024962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator.
    Xian Y; Federspiel JJ; Grau-Sepulveda M; Hernandez AF; Schwamm LH; Bhatt DL; Smith EE; Reeves MJ; Thomas L; Webb L; Bettger JP; Laskowitz DT; Fonarow GC; Peterson ED
    JAMA Neurol; 2016 Jan; 73(1):50-9. PubMed ID: 26551916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the drip-and-ship approach to delivering thrombolysis for acute ischemic stroke safe?
    Martin-Schild S; Morales MM; Khaja AM; Barreto AD; Hallevi H; Abraham A; Sline MR; Jones E; Grotta JC; Savitz SI
    J Emerg Med; 2011 Aug; 41(2):135-41. PubMed ID: 19272734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous Tissue Plasminogen Activator for Wake-Up Stroke: A Propensity Score-Matched Analysis.
    Anaissie JE; Monlezun DJ; Siegler JE; Waring ED; Dowell LN; Samai AA; George AJ; Kimbrough T; Berthaud J; Martin-Schild S
    J Stroke Cerebrovasc Dis; 2016 Nov; 25(11):2603-2609. PubMed ID: 27476340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use and Outcomes of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients ≥90 Years of Age.
    Arora R; Salamon E; Katz JM; Cox M; Saver JL; Bhatt DL; Fonarow GC; Peterson ED; Smith EE; Schwamm LH; Xian Y; Libman RB
    Stroke; 2016 Sep; 47(9):2347-54. PubMed ID: 27491734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospital variation in thrombolysis times among patients with acute ischemic stroke: the contributions of door-to-imaging time and imaging-to-needle time.
    Sauser K; Levine DA; Nickles AV; Reeves MJ
    JAMA Neurol; 2014 Sep; 71(9):1155-61. PubMed ID: 25023407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Clinical Care and In-Hospital Outcomes of Asian American and White Patients With Acute Ischemic Stroke.
    Song S; Liang L; Fonarow GC; Smith EE; Bhatt DL; Matsouaka RA; Xian Y; Schwamm LH; Saver JL
    JAMA Neurol; 2019 Apr; 76(4):430-439. PubMed ID: 30667466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Time to Treatment With Endovascular Reperfusion Therapy and Outcomes in Patients With Acute Ischemic Stroke Treated in Clinical Practice.
    Jahan R; Saver JL; Schwamm LH; Fonarow GC; Liang L; Matsouaka RA; Xian Y; Holmes DN; Peterson ED; Yavagal D; Smith EE
    JAMA; 2019 Jul; 322(3):252-263. PubMed ID: 31310296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why are acute ischemic stroke patients not receiving IV tPA? Results from a national registry.
    Messé SR; Khatri P; Reeves MJ; Smith EE; Saver JL; Bhatt DL; Grau-Sepulveda MV; Cox M; Peterson ED; Fonarow GC; Schwamm LH
    Neurology; 2016 Oct; 87(15):1565-1574. PubMed ID: 27629092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals.
    Schwamm LH; Ali SF; Reeves MJ; Smith EE; Saver JL; Messe S; Bhatt DL; Grau-Sepulveda MV; Peterson ED; Fonarow GC
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):543-9. PubMed ID: 24046398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000.
    Grotta JC; Burgin WS; El-Mitwalli A; Long M; Campbell M; Morgenstern LB; Malkoff M; Alexandrov AV
    Arch Neurol; 2001 Dec; 58(12):2009-13. PubMed ID: 11735774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.
    Albers GW; Bates VE; Clark WM; Bell R; Verro P; Hamilton SA
    JAMA; 2000 Mar; 283(9):1145-50. PubMed ID: 10703776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.